Spectral AI Strengthens Financial Position Ahead of FDA Submission
Spectral AI (NASDAQ: MDAI) has announced the completion of its debt obligations with Yorkville Advisors, strengthening its financial position. The company, which develops the AI-powered DeepView® System for burn healing prediction, maintains access to up to $17.5 million in additional financing through an existing standby equity purchase agreement.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential. The company is progressing toward its FDA submission with the aim of implementing its technology in burn care institutions across the United States.
Spectral AI (NASDAQ: MDAI) ha annunciato il completamento dei suoi obblighi di debito con Yorkville Advisors, rafforzando la sua posizione finanziaria. L'azienda, che sviluppa il sistema DeepView® basato su intelligenza artificiale per la previsione della guarigione delle ustioni, mantiene l'accesso a fino a 17,5 milioni di dollari in finanziamenti aggiuntivi attraverso un accordo di acquisto di capitale standby esistente.
Il sistema DeepView®, che ha ricevuto la designazione di Dispositivo Innovativo dalla FDA nel 2018, utilizza immagini multispettrali e algoritmi di intelligenza artificiale per prevedere il potenziale di guarigione delle ustioni. L'azienda sta procedendo verso la sua presentazione alla FDA con l'obiettivo di implementare la sua tecnologia nelle istituzioni di cura delle ustioni negli Stati Uniti.
Spectral AI (NASDAQ: MDAI) ha anunciado la finalización de sus obligaciones de deuda con Yorkville Advisors, fortaleciendo su posición financiera. La empresa, que desarrolla el sistema DeepView® impulsado por inteligencia artificial para la predicción de la curación de quemaduras, mantiene acceso a hasta 17,5 millones de dólares en financiamiento adicional a través de un acuerdo existente de compra de capital de reserva.
El sistema DeepView®, que recibió la designación de Dispositivo Innovador por la FDA en 2018, utiliza imágenes multispectrales y algoritmos de IA para predecir el potencial de curación de quemaduras. La empresa avanza hacia su presentación a la FDA con el objetivo de implementar su tecnología en instituciones de atención de quemaduras en los Estados Unidos.
스펙트럴 AI (NASDAQ: MDAI)가 요크빌 어드바이저(Yorkville Advisors)와의 부채 의무를 완료했다고 발표하며 재무 상태를 강화했습니다. 인공지능 기반의 DeepView® 시스템을 개발하는 이 회사는 기존의 대기 자본 구매 계약을 통해 최대 1,750만 달러의 추가 자금에 접근할 수 있습니다.
DeepView® 시스템은 2018년에 FDA 혁신 기기 지정을 받았으며, 다중 스펙트럼 이미징과 AI 알고리즘을 활용하여 화상의 치유 가능성을 예측합니다. 이 회사는 미국 전역의 화상 치료 기관에 기술을 구현하기 위해 FDA 제출을 향해 나아가고 있습니다.
Spectral AI (NASDAQ: MDAI) a annoncé l'achèvement de ses obligations de dette avec Yorkville Advisors, renforçant ainsi sa position financière. L'entreprise, qui développe le système DeepView® alimenté par l'IA pour la prédiction de la guérison des brûlures, a accès à jusqu'à 17,5 millions de dollars de financement supplémentaire grâce à un accord d'achat d'équité de réserve existant.
Le système DeepView®, qui a reçu la désignation de Dispositif Innovant par la FDA en 2018, utilise l'imagerie multispectrale et des algorithmes d'IA pour prédire le potentiel de guérison des brûlures. L'entreprise progresse vers sa soumission à la FDA dans le but de mettre en œuvre sa technologie dans les établissements de soins des brûlures à travers les États-Unis.
Spectral AI (NASDAQ: MDAI) hat den Abschluss ihrer Schuldenverpflichtungen mit Yorkville Advisors bekannt gegeben, was ihre finanzielle Position stärkt. Das Unternehmen, das das KI-gestützte DeepView®-System zur Vorhersage der Heilung von Verbrennungen entwickelt, hat Zugang zu bis zu 17,5 Millionen Dollar an zusätzlicher Finanzierung durch eine bestehende Standby-Eigenkapitalvereinbarung.
Das DeepView®-System, das 2018 die FDA-Innovationsgerätebezeichnung erhielt, nutzt multispektrale Bildgebung und KI-Algorithmen, um das Heilungspotenzial von Verbrennungen vorherzusagen. Das Unternehmen arbeitet auf die Einreichung bei der FDA hin, mit dem Ziel, seine Technologie in Verbrennungsbehandlungszentren in den Vereinigten Staaten zu implementieren.
- Cleared all debt obligations with Yorkville Advisors
- Access to $17.5 million in additional financing through standby equity purchase agreement
- Previously received FDA Breakthrough Device Designation for DeepView® System
- Potential future dilution from $17.5M standby equity purchase agreement
Insights
The clearance of debt obligations with Yorkville Advisors marks a strategically timed financial restructuring for Spectral AI, particularly important as the company approaches its FDA submission phase. For medical device companies, maintaining a strong balance sheet during the regulatory review process is essential, as it demonstrates financial sustainability to regulators and potential commercial partners.
The retention of
The timing of this financial restructuring is particularly noteworthy given their previous FDA Breakthrough Device Designation for the DeepView® System. This designation, which can accelerate the regulatory review process, typically requires companies to maintain robust financial resources to support expedited development and potential commercialization. The convergence of debt clearance and maintained financing access positions Spectral AI more favorably for both the FDA submission process and potential commercial launch preparations.
However, investors should note that while the standby equity purchase agreement provides financial flexibility, any future draws on this facility would result in share dilution. The company's ability to minimize the need for additional capital raises will depend largely on the efficiency of their FDA submission process and the timeline to potential approval and commercialization.
DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the satisfaction of its final remaining obligations under the Company’s debt facility with Yorkville Advisors. The Company retains access to additional financing of up to
“I am pleased to share this milestone as we continue advancing toward our FDA submission and work to bring our technology to burn care institutions across the U.S.,” said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is a predictive device that offers clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView® System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
What is the current status of Spectral AI's (MDAI) debt facility with Yorkville Advisors?
How much additional financing does Spectral AI (MDAI) have access to?
When did Spectral AI's DeepView System receive FDA Breakthrough Device Designation?
What is the purpose of Spectral AI's (MDAI) DeepView System?
What is Spectral AI's (MDAI) next major regulatory milestone?
